Significance of HIF-1-active cells in angiogenesis and radioresistance

Oncogene

Volumn 26, Issue 54, 2007, Pages 7508-7516

  Harada, H ^a   Kizaka Kondoh, S ^a   Li, G ^a,c   Itasaka, S ^a   Shibuya, K ^a   Inoue, M ^b   Hiraoka, M ^a  

^a KYOTO UNIVERSITY   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

Angiogenesis; HIF 1; Radiotherapy; Tumor hypoxia

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; LUCIFERASE; PROTEIN; TAT ODD PROCASPASE 3 PROTEIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANGIOGENESIS; ARTICLE; CANCER INHIBITION; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IONIZING RADIATION; IRRADIATION; PRIORITY JOURNAL; RADIATION; RADIOSENSITIVITY; TUMOR CELL; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; CELL DEATH; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PROMOTER REGIONS (GENETICS); RADIATION, IONIZING; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION, HETEROLOGOUS; UTERINE CERVICAL NEOPLASMS;

EID: 36749029349     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210556     Document Type: Article

References (38)

1. Abdollahi A, Lipson KE, Han X, Krempien R, Trinh T, Weber KJ et al. (2003). SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 63: 3755-3763.
2. Brown JM. (1999). The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59: 5863-5870.
3. Brown JM, Wilson WR. (2004). Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447.
4. Bruick RK, McKnight SL. (2001). A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337-1340.
5. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC et al. (2000). Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275: 25733-25741.
6. de Candia P, Solit DB, Giri D, Brogi E, Siegel PM, Olshen AB et al. (2003). Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc Natl Acad Sci USA 100: 12337-12342.
7. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR et al. (2001). C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54.
8. Fernandes-Alnemri T, Litwack G, Alnemri ES. (1994). CPP32, a novel human apoptotic protein with homology toaenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 269: 30761-30764.
9. Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H et al. (2001). Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61: 2413-2419.
10. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM et al. (1999). Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59: 3374-3378.
11. Harada H, Hiraoka M, Kizaka-Kondoh S. (2002). Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res 62: 2013-2018.
12. Harada H, Kizaka-Kondoh S, Hiraoka M. (2005). Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 4: 182-193.
13. Harada H, Kizaka-Kondoh S, Hiraoka M. (2006). Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1a containing Pro564. FEBS Lett 580: 5718-5722.
14. Harris AL. (2002). Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47.
15. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26: 45-50.
16. Huang LE, Gu J, Schau M, Bunn HF. (1998). Regulation of hypoxia-inducible factor 1 alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95: 7987-7992.
17. Inoue M, Mukai M, Hamanaka Y, Tatsuta M, Hiraoka M, Kizaka-Kondoh S. (2004). Targeting hypoxic cancer cells with a protein prodrug is effective in experimental malignant ascites. Int J Oncol 25: 713-720.
18. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L. (1999). Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem 274: 6519-6525.
19. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW. (2000). Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 97: 10430-10435.
20. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. (2003). Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 94: 1021-1028.
21. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS et al. (2003). 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3: 363-375.
22. Moeller BJ, Cao Y, Li CY, Dewhirst MW. (2004). Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5: 429-441.
23. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE et al. (2000). Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2: 423-427.
24. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR, Danish Head and Neck Cancer Study Group. (2005). Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6: 757-764.
25. Raleigh JA, Calkins-Adams DP, Rinker LH, Ballenger CA, Weissler MC, Fowler Jr WC et al. (1998). Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 58: 3765-3768.
26. Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RH et al. (2002). Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62: 4316-4324.
27. Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M et al. (2005). Tirapazamine, Cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23: 79-87.
28. Rowinsky EK. (1999). Novel radiation sensitizers targeting tissue hypoxia. Oncology 13: 61-70.
29. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. (1999). In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569-1572.
30. Semenza GL. (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
31. Semenza GL, Wang GL. (1992). A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447-5454.
32. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P. (2005). Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res 65: 7259-7266.
33. Tanimoto K, Makino Y, Pereira T, Poellinger L. (2000). Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 19: 4298-4309.
34. Vaupel P. (2001). Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14: 198-206.
35. Vaupel P, Kallinowski F, Okunieff P. (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465.
36. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. (2003). The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2: 235-243.
37. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS et al. (2003). YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95: 516-525.
38. Zackrisson B, Mercke C, Strander H, Wennerberg J, Cavallin-Stahl E. (2003). A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol 42: 443-461.